Issue Date: September 11, 2017
New synthetic heparin could improve blood-thinning treatments
A new synthetic version of the sulfated polysaccharide heparin that could be safer or have more-reversible activity than currently approved versions of the anticoagulant has been produced in quantities that begin to approach those needed for commercialization. Three types of heparins are currently approved as blood thinners to treat clotting disorders and prevent clotting in people undergoing kidney dialysis and surgery. Unfractionated heparin and low-molecular-weight heparin, derived from pig intestines, are . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society